Lipoglycopeptide

Oct 24, 2017

Theravance Biopharma to Present New Data from Studies of VIBATIV® (telavancin) and Revefenacin (TD-4208) at the 2017 CHEST Annual Meeting

Oct 03, 2017

Theravance Biopharma to Present New Data from Multiple Studies of VIBATIV® (telavancin) at IDWeek(TM) 2017

Jun 21, 2017

Cardiome Announces Licensing Agreement for XYDALBA(TM) (Dalbavancin Hydrochloride) to Support Planned Commercialization in Israel